Is it worth buying Zimmer Biomet stock at a price of $90.38? If this question is on your mind, make sure to check out the fundamentals of this Specialty Industrial Machinery Large-Cap company:
-
Zimmer Biomet has logged a -25.5% 52 week change, compared to 8.9% for the S&P 500
-
ZBH has an average analyst rating of hold and is -18.94% away from its mean target price of $111.5 per share
-
Its trailing earnings per share (EPS) is $4.5, which brings its trailing Price to Earnings (P/E) ratio to 20.1. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $8.6 and its forward P/E ratio is 10.5
-
The company has a Price to Book (P/B) ratio of 1.45 in contrast to the Health Care sector's average P/B ratio is 3.19
-
The current ratio is currently 1.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
ZBH has reported YOY quarterly earnings growth of 8.3% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $1.3 Billion and the average free cash flow growth rate is 0.9%
-
Zimmer Biomet's revenues have an average growth rate of 3.2% with operating expenses growing at 1.2%. The company's current operating margins stand at 16.7%